Given the decisive role of BCR-ABL in the development of CML, TKI-based therapy has been regarded as the gold standard for the treatment of CML since the excellent clinical performance of the first TKI, imatinib. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.